OverviewSuggest Edit

Horizon Therapeutics is a biopharmaceutical company building a pipeline and exploring potential uses for medicines. It offers medicines to treat rare, inflammation, and rheumatic diseases. In addition, the company provides patient advocacy, disease education as well as patient support and savings programs.

TypePublic
Founded2008
HQBallsbridge, IE
Websitehorizontherapeutics.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Dec 2018)1,000
Revenue (FY, 2018)$1.2 B(+15%)
Share Price (Nov 2019)$30.2

Key People/Management at Horizon Therapeutics

Timothy Walbert

Timothy Walbert

Chairman, President and Chief Executive Officer
Brian K. Beeler

Brian K. Beeler

Executive Vice President, General Counsel
Robert F. Carey

Robert F. Carey

Executive Vice President, Chief Business Officer
Paul W. Hoelscher

Paul W. Hoelscher

Executive Vice President, Chief Financial Officer
Vikram Karnani

Vikram Karnani

Executive Vice President, Chief Commercial Officer
Irina Konstantinovsky

Irina Konstantinovsky

Executive Vice President, Chief Human Resources Officer
Show more

Horizon Therapeutics Office Locations

Horizon Therapeutics has offices in Ballsbridge, Chicago, Lake Forest, Novato and in 3 other locations
Ballsbridge, IE (HQ)
Connaught House Burlington Rd
Mannheim, DE
13 Joseph-Meyer-Straße
Reinach, CH
17 Kägenstrasse
Chicago, US
150 S Wacker Dr #3200
Lake Forest, US
Landmark of Lake Forest 2, 150 S Saunders Rd
Novato, US
3 Hamilton Landing #260Novato
Show all (7)

Horizon Therapeutics Financials and Metrics

Horizon Therapeutics Revenue

Embed Graph
View revenue for all periods
Horizon Therapeutics's revenue was reported to be $1.21 b in FY, 2018
USD

Revenue (Q3, 2019)

335.5m

Gross profit (Q3, 2019)

245.5m

Gross profit margin (Q3, 2019), %

73.2%

Net income (Q3, 2019)

18.2m

EBIT (Q3, 2019)

48.6m

Market capitalization (12-Nov-2019)

5.7b

Closing stock price (12-Nov-2019)

30.2

Cash (30-Sep-2019)

884.0m
Horizon Therapeutics's current market capitalization is $5.7 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

74.0m297.0m757.0m981.1m1.1b1.2b

Revenue growth, %

301%155%30%

Cost of goods sold

14.6m76.8m219.5m393.3m546.3m422.3m

Gross profit

59.4m220.2m537.5m587.8m510.0m785.3m
Quarterly
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

80.5m218.8m859.6m509.1m751.4m958.7m

Accounts Receivable

16.0m78.4m210.4m305.7m367.4m464.7m

Inventories

8.7m14.4m18.4m174.8m61.7m50.8m

Current Assets

110.8m329.2m1.1b1.0b1.2b1.5b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(149.0m)(263.6m)39.5m(166.8m)(410.5m)(74.2m)

Depreciation and Amortization

9.3m34.0m138.3m221.8m283.4m275.7m

Inventories

(3.4m)7.2m12.2m67.6m108.4m10.3m

Accounts Payable

3.9m9.4m(8.4m)32.1m(16.5m)(4.6m)
USDY, 2019

Financial Leverage

2.4 x
Show all financial metrics

Horizon Therapeutics Online and Social Media Presence

Embed Graph

Horizon Therapeutics News and Updates

UPDATE: Horizon Pharma stock soars 17% premarket on positive trial of eye disease treatment

Horizon Pharma plc shares soared 17% in premarket trade Thursday, after the company announced positive results in a late-stage trial of a treatment for active thyroid eye disease, or TED. The company said the phase 3 trial of teprotumumab met its primary endpoint of improving proptosis, or bulging …

Horizon Therapeutics Blogs

Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer

Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer Content Import Wed, 08/28/2019 - 16:30 Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer 08/28/19 This release is a back…

American Journal of Ophthalmology (AJO) Publishes Review Highlighting Lack of Treatments for Active Thyroid Eye Disease (TED)

DUBLIN --(BUSINESS WIRE)--Aug. 19, 2019-- A rigorous evaluation of the state of care for thyroid eye disease (TED) published in the American Journal of Ophthalmology (AJO) highlights the lack of current therapies to adequately treat the disease. The invited ‘Perspective’ discusses the potential for

Horizon Therapeutics plc to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

DUBLIN --(BUSINESS WIRE)--Aug. 19, 2019-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the company will participate in the following conference in September: Morgan Stanley 17 th Annual Global Healthcare Conference Date: Sept. 10, 2019 Presentation Time: 10 a.m.

Horizon Therapeutics plc Collaborates with Rare Disease Advocates to Elevate Resources and Shared Experiences Through Launch of #RAREis™ Community Website

-- New website features resources, transitions support and personal stories of people living with rare diseases -- DUBLIN --(BUSINESS WIRE)--Aug. 14, 2019-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of RAREisCommunity.com , a go-to resource for the more than 350 million

Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance

-- Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million ; Adjusted EBITDA of $124.1 Million -- -- Quarterly Orphan and Rheumatology Segment Net Sales Increased 11 Percent to $223.5 Million ; KRYSTEXXA ® Second-Quarter 2019 Net Sales

Horizon Therapeutics plc Announces Teprotumumab Expanded Access Program

Horizon Therapeutics plc Announces Teprotumumab Expanded Access Program Content Import Thu, 08/01/2019 - 10:46 Horizon Therapeutics plc Announces Teprotumumab Expanded Access Program 08/01/19 This release is a backfill from a News Wire General …
Show more

Horizon Therapeutics Frequently Asked Questions

  • When was Horizon Therapeutics founded?

    Horizon Therapeutics was founded in 2008.

  • Who are Horizon Therapeutics key executives?

    Horizon Therapeutics's key executives are Timothy Walbert, Brian K. Beeler and Robert F. Carey.

  • How many employees does Horizon Therapeutics have?

    Horizon Therapeutics has 1,000 employees.

  • What is Horizon Therapeutics revenue?

    Latest Horizon Therapeutics annual revenue is $1.2 b.

  • What is Horizon Therapeutics revenue per employee?

    Latest Horizon Therapeutics revenue per employee is $1.2 m.

  • Who are Horizon Therapeutics competitors?

    Competitors of Horizon Therapeutics include Bausch Health Companies, BioDelivery Sciences International and Perrigo.

  • Where is Horizon Therapeutics headquarters?

    Horizon Therapeutics headquarters is located at Connaught House Burlington Rd, Ballsbridge.

  • Where are Horizon Therapeutics offices?

    Horizon Therapeutics has offices in Ballsbridge, Chicago, Lake Forest, Novato and in 3 other locations.

  • How many offices does Horizon Therapeutics have?

    Horizon Therapeutics has 7 offices.